UvA-DARE (Digital Academic Repository)

Reduced sulfation of muc5b is linked to xerostomia in patients with Sjögren syndrome

Alliende, C.; Kwon, Y.-J.; Brito, M.; Molina, C.; Aguilera, S.; Pérez, P.; Leyton, L.; Quest, A.F.G.; Mandel, U.; Veerman, E.; Espinosa, M.; Clausen, H.; Leyton, C.; Romo, R.; González, S.

DOI

[10.1136/ard.2007.078246](https://doi.org/10.1136/ard.2007.078246)

Publication date

2008

Published in

Annals of the Rheumatic Diseases

[Link to publication](#)

Citation for published version (APA):

Alliende, C., Kwon, Y.-J., Brito, M., Molina, C., Aguilera, S., Pérez, P., Leyton, L., Quest, A. F. G., Mandel, U., Veerman, E., Espinosa, M., Clausen, H., Leyton, C., Romo, R., & González, S. (2008). Reduced sulfation of muc5b is linked to xerostomia in patients with Sjögren syndrome. *Annals of the Rheumatic Diseases*, 67, 1480-1487.
<https://doi.org/10.1136/ard.2007.078246>

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (<https://dare.uva.nl>)

Reduced sulfation of muc5b is linked to xerostomia in patients with Sjögren syndrome

C Allende, Y-J Kwon, M Brito, C Molina, S Aguilera, P Pérez, L Leyton, A F G Quest, U Mandel, E Veerman, M Espinosa, H Clausen, C Leyton, R Romo and M-J González

Ann Rheum Dis 2008;67:1480-1487; originally published online 12 Nov 2007; doi:10.1136/ard.2007.078246

Updated information and services can be found at:

<http://ard.bmj.com/cgi/content/full/67/10/1480>

These include:

Data supplement

"web only appendix"

<http://ard.bmj.com/cgi/content/full/67/10/1480/DC1>

References

This article cites 31 articles, 14 of which can be accessed free at:

<http://ard.bmj.com/cgi/content/full/67/10/1480#BIBL>

1 online articles that cite this article can be accessed at:

<http://ard.bmj.com/cgi/content/full/67/10/1480#otherarticles>

Rapid responses

You can respond to this article at:

<http://ard.bmj.com/cgi/eletter-submit/67/10/1480>

Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

To order reprints of this article go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to *Annals of the Rheumatic Diseases* go to:

<http://journals.bmj.com/subscriptions/>

Reduced sulfation of muc5b is linked to xerostomia in patients with Sjögren syndrome

C Alliende,¹ Y-J Kwon,¹ M Brito,¹ C Molina,² S Aguilera,³ P Pérez,¹ L Leyton,¹ A F G Quest,¹ U Mandel,⁴ E Veerman,⁵ M Espinosa,¹ H Clausen,⁴ C Leyton,¹ R Romo,⁶ M-J González¹

► Supplementary table 1 is published online only at <http://ard.bmj.com/content/vol67/issue10>

¹ University of Chile, Santiago, Chile; ² Mayor University, Santiago, Chile; ³ INDISA Clinic-Andrés Bello University, Santiago, Chile; ⁴ University of Copenhagen, Copenhagen, Denmark; ⁵ University of Amsterdam, Amsterdam, The Netherlands; ⁶ Santa María Clinic, Santiago, Chile

Correspondence to: M-J González, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Casilla 70061, Santiago 7, Chile; jgonzale@med.uchile.cl

The first four authors contributed equally to this work

Accepted 1 November 2007
Published Online First
12 November 2007

ABSTRACT

Objectives: MUC5B contains sulfated and sialylated oligosaccharides that sequester water required for moisturising the oral mucosa. Xerostomia, in patients with Sjögren syndrome, is generally associated with reduced quantities, rather than altered properties, of saliva. Here, we determined the amount of MUC5B (mRNA and protein) as well as sulfation levels in salivary glands of patients with normal or altered unstimulated salivary flow. Localisation of MUC5B and sulfated MUC5B, as well as total levels sulfated groups were determined and compared with acini basal lamina disorganisation.

Patients and methods: In all, 18 patients with normal or altered unstimulated salivary flow and 16 controls were studied. MUC5B mRNA and protein were evaluated in salivary glands by semiquantitative RT-PCR and Western blot analysis. MUC5B sulfation was determined by Western blotting. MUC5B and sulfo-Lewis^a antigen localisation were assessed by immunohistochemistry. The total amount of sulfated oligosaccharides was determined microdensitometrically.

Results: No significant differences were detected in MUC5B mRNA and protein levels between controls and patients, while sulfo-Lewis^a antigen levels were lower in patients. The number of sulfo-Lewis^a positive mucous acini was reduced in patients but no correlation was observed between lower levels of sulfation and unstimulated salivary flow. Microdensitometric data confirmed the presence of reduced sulfated oligosaccharides levels in mucous acini from patients with highly disorganised basal lamina.

Conclusion: Disorganisation of the basal lamina observed in patients with Sjögren syndrome may lead to dedifferentiation of acinar mucous cells and, as a consequence, alter sulfation of MUC5B. These changes are suggested to represent a novel mechanism that may explain xerostomia in these patients.

Primary Sjögren syndrome is an autoimmune exocrinopathy. Secretory activity of salivary and lacrimal glands is highly compromised, and severe dryness of the mouth and the eyes are the consequence.¹ Autoantibodies against muscarinic-M3 receptors,² variations in cytokine levels,³ glandular denervation,⁴ acinar atrophy,⁵ redistribution of aquaporin-5 in the acinar cells⁶ and increased levels of cholinesterase⁷ are the most frequent molecular and morphological changes associated with symptoms of dryness. However, only some of these changes are observed in these patients. Thus, correlating the observed changes with specific symptoms, such as dryness, remains as a controversial issue in the field.⁷⁻⁸

Morphological changes in the secretory granules have been consistently observed in all patients evaluated⁹⁻¹⁰ and could be considered one of the most reliable indicators for this disease. In non-obese diabetic (NOD) mice, an animal model for Sjögren syndrome, changes in secretory granule morphology and distribution of key effectors of exocytosis are apparent at 4 weeks after birth, which may be taken to indicate that disease onset occurs prior to lymphocyte infiltration.¹¹ A better understanding of events specifically associated with early alterations in secretory granule function should be insightful.

MUC5B, the predominant mucin in salivary gland high molecular weight mucous glycoprotein 1 preparations, is synthesised by mucous acini and glycosylated to varying extents.¹² The associated carbohydrates are heterogeneous and include neutral, sulfated and sialylated oligosaccharides.¹³ Sulfated and sialylated mucins retain large amounts of water and contribute thereby to generating the hydrophilic gel essential for lubrication of the oral epithelium.¹⁴

Previous studies revealed high levels of high molecular weight mucous glycoprotein 1 in resting saliva of patients with Sjögren syndrome.¹⁵ These authors attributed the changes to either the reduced presence of water or, alternatively, to a limitation in the capacity to retain water and suggested that this might explain xerostomia.¹⁵

The objective of this study was to evaluate whether symptoms of xerostomia were linked to reduced salivary flow or qualitative/quantitative changes (eg, post-translational modifications) in the MUC5B produced.

PATIENTS AND METHODS

A total of 18 patients (females) with primary Sjögren syndrome (mean (SD) age = 50.5 (12.3) years) diagnosed according to the American-European Consensus Group criteria,¹⁶ were selected for these studies. Several tests were performed to identify ocular, oral and serological involvement. The focus score was ≥ 1 in patients with 50–80% of remnant parenchyma. Dry eye and mouth symptoms were observed in all patients. Unstimulated salivary flow was lower than 1.5 ml per 15 min in 11/18 patients. Additionally, scintigraphy and Schirmer test results were altered. Patients had neither been treated with corticosteroids, hydroxychloroquine, or immunosuppressive drugs for at least 1 month before biopsies were obtained.

Additional clinical data are included in the Supplementary material.

The control group was composed of 16 subjects (females) (mean (SD) age = 43.09 (12.18) years) who had consulted their doctors because of oral and ocular dryness symptoms over more than 3 months, but who did not fulfil the criteria for Sjögren syndrome. Serological, scintigraphy and unstimulated whole salivary flow data were normal in these patients. Biopsied labial salivary glands were normal, with scarce and scattered distribution of mononuclear cells, well-preserved parenchyma, and lack of fibrous or adipose tissue. Control individuals were free of systemic diseases and did not use drugs that could affect the function of the exocrine glands. Biopsies were obtained following informed consent of the control group and patients. No significant differences ($p = 0.12$) between controls and patients according to age were detectable. This study was conducted according to the guidelines of the Ethics Committee of the Faculty of Medicine, University of Chile.

Biopsies

Labial salivary gland biopsies were obtained in the morning (after at least 2 h of fasting), using the technique described by Daniels.¹⁷ Glands were fixed for immunohistochemistry using two different conditions. One half of the gland was treated with alcoholic Bouin fixative (MUC5B and sulfo-Lewis^a antigen) and the other half was fixed in 1% paraformaldehyde (laminin) and then embedded in paraffin. For RNA and protein preparations, the glands were snap-frozen in liquid nitrogen and stored at -70°C .

RNA extraction/semiquantitative RT-PCR/Preparation of protein extracts

Experiments were performed essentially as previously described^{18–20} (see also Supplementary material).

Western blotting

Gland protein extracts were prepared as previously described.^{18–19} Aliquots of 25 μg of proteins were separated on 6% SDS-polyacrylamide gels under reducing conditions and transferred to nitrocellulose over 15 h at 60 mA and 4°C . Membranes were incubated with PANH2 (a mouse antibody, recognises partially deglycosylated MUC5B) or F2 (a mouse antibody, recognises the $\text{SO}_3\text{Gal}\beta 1\text{-3GlcNAc}$ moiety of sulfo-Lewis^a antigen, both obtained from the European Consortium of Mucins), diluted 1:10 or 1:50 in Tris buffered saline/Tween (TBST), respectively, for 2 h at room temperature. Alternatively, membranes were incubated with the anti-actin antibody (MP Biomedicals, Aurora, Ohio, USA) diluted 1:5000 in blocking solution. Then, blots were incubated with anti-mouse IgG-HRP (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA) (dilution 1:5000) for 1 h at room temperature, and horseradish peroxidase (HRP) was detected with ECL as described.¹⁸ MUC5B and Sulfo-MUC5B bands were analysed densitometrically (UN-Scan-IT, Silk Scientific Corporation, Orem, Utah, USA) and values obtained were normalised to those of β -actin. An amount of 10–70 μg of total protein yielded a densitometric β -actin signal within the linear range.

Immunohistochemistry analysis

Sections used for MUC5B and sulfo-Lewis^a antigen detections were blocked to prevent non-specific antibody binding with 0.25% casein in phosphate buffered saline (PBS) and incubated for 20 h at 4°C with non-diluted PANH2 or F2 diluted 1:50 in

1% bovine serum albumin/PBS, followed by a biotinylated secondary antibody and a streptavidin-peroxidase conjugate (Dako, Carpinteria, California, USA). The reaction was developed with 3',3'-diaminobenzidine. Mayer haematoxylin was used for counterstaining. As a negative control, a mouse IgG1 (PANH2) or IgM (F2) recognising an epitope not present in mammalian tissues was employed. For additional information concerning PANH2 and F2 antibodies, see Supplementary material. Laminin was detected as previously described⁹ and these sections were also stained with Alcian blue pH 1.0 for 15 min at room temperature, (for details see Supplementary material).

Quantification of the histochemistry reaction of sulfated mucins

Gland sections were stained with Alcian blue pH 1.0 to identify sulfated mucins. Staining intensity was measured with a MPM-400 microdensitometer (Carl Zeiss, Jena, Germany). For each biopsy, 50 random fields containing parenchyma were analysed and the mean value was expressed in arbitrary units of absorbance (AU). The data were evaluated using the Systat 9.0 program (SPSS, Chicago, Illinois, USA).

Statistical analysis

Normalised data of mRNA, proteins and sulfo-Lewis^a antigen were averaged to calculate mean values and the standard deviation. A Mann-Whitney U test and non-parametric Spearman correlation were used. Microdensitometric measurements of sulfated mucins were compared by unpaired Student t test analysis. p Values less than 0.05 were considered significant.

RESULTS

mRNA and protein levels of MUC5B

As shown in fig 1A,B, no significant changes in relative mRNA expression levels were found when comparing samples from patients ($n = 10$) with control individuals ($n = 9$) ($p = 0.07$); however, a tendency towards decreased mRNA levels was detected in patients. The PANH2 antibody, which recognises partially glycosylated MUC5B, was employed for MUC5B protein determination.²¹ Two broad and diffuse bands were observed, one migrating with an apparent molecular weight somewhat larger than 200 kDa and the second being so large that it was retained in the stacking gel. The electrophoretic pattern was similar between patients and controls. No significant differences ($p = 0.33$) were found when bands were analysed by scanning densitometry either separately (not shown) or together (fig 1C,D).

Localisation of MUC5B

MUC5B was detected in mucous acini from controls and patients (fig 2A–F). MUC5B levels were similar in all mucous acinar cells present in the normal gland sections (fig 2A) and localised to the basal region of these cells (fig 2B). Double staining with PANH2/Alcian blue pH 1.0 revealed sulfated secretion products in the apical region of mucous acinar cells in controls (fig 2C). In patients, MUC5B was detectable in the basal and apical zones of mucous acinar cells (fig 2D,E). Stronger immunoreactivity was detected in mucous acini adjacent to foci of inflammatory cells (fig 2D,E), while in regions without foci; the intensity was similar to those observed in controls (fig 2F). In patients, increased immunoreactivity for MUC5B and particularly presence in apical suggests that MUC5B glycosylation was decreased.

Extended report

Figure 1 MUC5B mRNA and protein levels in labial salivary glands from patients with Sjögren syndrome and healthy control individuals. A. MUC5B mRNA was detected by semi-quantitative RT-PCR, as a single band of 400 bp and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a band of 650 bp. C. Gland extracts were tested by immunoblotting with monoclonal anti-human MUC5B antibody (PANH2) followed by anti-mouse IgG conjugated to horseradish peroxidase (HRP). β-actin was used as a loading control. B and D. Quantification of amplicons and protein bands normalised to GAPDH and β-actin levels, respectively; p values of patients group compared with healthy controls are indicated. Values shown were averaged from nine control individuals for mRNA and five for protein data. Alternatively, material from 10 patients was used for mRNA and from 6 patients for protein studies. Data are representative of three independent experiments. p Values <0.05 were considered statistically significant.

Levels of sulfo-MUC5B

The degree of sulfation in a specific and well characterised oligosaccharide, the sulfo-Lewis^a antigen, was analysed using the monoclonal antibody F2 that recognises the antigen (SO₃Galβ1-3GlcNAc). Sulfo-Lewis^a levels (fig 3A,B) were notably decreased in gland extracts from patients (n = 10) as compared with controls (n = 9) (p<0.001). The electrophoretic pattern for sulfo-Lewis^a antigen was similar to the pattern obtained for MUC5B; however, the upper band of sulfo-Lewis^a antigen (located in the stacking gel) was broader and of greater intensity than the one detected for MUC5B, particularly in controls. This is probably indicative of a heterogenic population of sulfo-Lewis^a glycoforms.

Localisation of sulfo-Lewis^a antigen

The substantial decrease in sulfo-Lewis^a antigen observed in salivary gland extracts from patients was also evaluated in gland sections. As shown in fig 4, similar staining patterns were observed with the F2 antibodies in controls (A–D) and patients (E–G): for one group of mucous acini generalised cytoplasmic staining was apparent (fig 4A,E), in another group a mosaic-like staining pattern was detected (fig 4B,F), and in a third group no staining of cells could be detected (fig 4C,G). In fig 4C, gland sections were sequentially stained for MUC5B (dark brown signal) and sulfo-Lewis^a antigen (light brown signal). In some

mucous acini only MUC5B staining was detected in basal regions of acinar cells, while in neighbouring mucous acini MUC5B and sulfo-Lewis^a antigen were apparent. These results suggest that sulfo-Lewis^a antigen-negative acini expressed MUC5B lacking sulfation in (SO₃Galβ1-3GlcNAc).

To test whether other sulfated groups were present in sulfo-Lewis^a negative/MUC5B positive mucous acini, these sections were also stained with Alcian blue pH 1.0 (fig 4D). Indeed, some acini were triple positive for MUC5B/sulfo-Lewis^a/Alcian blue while in others only MUC5B and Alcian blue were detected (fig 4D). Signal intensity was similar in sulfo-Lewis^a positive acini of patients and controls (fig 4A–C, E–G). However, the number of sulfo-Lewis^a positive mucous acini was dramatically reduced in patients (compare fig 4E,F,G). Occasionally, in areas infiltrated with inflammatory cells, disrupted ducts with mucin between these cells were observed (fig 4H). No signal was detected with the IgM used as negative control for the F2 antibody (data not shown).

Relationship between sulfo-Lewis^a positive mucous acini and salivary flow

The number of sulfo-Lewis^a positive mucous acini was expressed as a percentage of the total number of mucous acini evaluated in three gland sections from either patient or control individuals. Each section contains at least 300 mucous acini. The

Figure 2 Localisation of MUC5B in labial salivary glands from control individuals (A–C) and patients with Sjögren syndrome (D–F). A. Gland section showing MUC5B in mucous acini. B. MUC5B in basal region of mucous acinar cells. C. Double staining for MUC5B/Alcian blue. D. Gland region near focus of inflammatory cells. E. MUC5B in basal and apical region of mucous acinar cells. F. Gland region far from a focus of inflammatory cells. Images are representative of data from 16 controls and 18 patients. Bars: correspond to 100 μ m (A, D and F), or 20 μ m (B, C and E). m: mucous acinus, s: serous acinus.

Figure 3 Levels of sulfo-Lewis^x antigen expression in labial salivary glands from patients with Sjögren syndrome and control individuals. A. Gland extracts from the same individuals used in fig 1C were probed separately by immunoblotting either with F2 antibody or with anti- β -actin as a control. Western blot analysis revealed two wide bands located in the same molecular weight region as those detected for MUC5B. B. Densitometric analysis was used to quantify sulfo-Lewis^x positive bands that were normalised to β -actin values. Data are representative of three independent experiments with five control individuals and six patients. p Values < 0.05 were considered statistically significant.

unstimulated salivary flow data indicate that 7/18 patients had a flow rate greater than 1.5 ml/15 min, while for 11/18 patients the flow rate was less than 1.5 ml/15 min (fig 5A). Interestingly, in both patient groups, unlike controls, ~80% of mucous acini were negative for the sulfo-Lewis^x antigen, ($p < 0.001$; fig 5B). The percentage of sulfo-Lewis^x positive mucous acini was associated with the unstimulated salivary flow, but no correlation was found in either controls ($\rho = -0.346$) or patients ($\rho = 0.168$) (see fig 5C,D).

Microdensitometric analysis of total sulfate in mucous acini

The basal lamina has previously been shown to be altered in acini and ducts of salivary glands from patients with Sjögren syndrome.⁹ The aforementioned results showed information concerning a single type of sulfated oligosaccharide ($\text{SO}_3\text{Gal}\beta 1-3\text{GlcNAc}$) were showed. Here, we consider correlating total levels of sulfated oligosaccharides with basal lamina integrity by double staining using Alcian blue pH 1.0 and an antibody directed against laminin. Microdensitometric analysis of Alcian blue pH 1.0 staining was significantly lower in patients than in controls ($p = 0.04$; fig 6A). This reaction was associated with a uniform and strong laminin signal in control individuals (fig 6B). Conversely, weak positive staining for Alcian blue pH 1.0 in patients correlated with decreased laminin immunoreactivity (fig 6C).

DISCUSSION

Messenger RNA, protein and sulfation levels of MUC5B as well as the localisation of MUC5B protein and sulfated moieties in labial salivary glands from patients with Sjögren syndrome were evaluated here. Significant differences were not detectable for mRNA or protein levels when comparing patients with controls

Extended report

Figure 4 Localisation of sulfo-Lewis^a antigen in labial salivary glands from control individuals (A–D) and patients with Sjögren syndrome (E–H). A. mucous acini completely stained. B. mucous acini with mosaic staining pattern. C. Sequential staining for MUC5B (dark brown) and sulfo-Lewis^a antigen (light brown). D. Triple staining (MUC5B/sulfo-Lewis^a/Alcian blue). Mucous acini that were either sulfo-Lewis^a negative/MUC5B positive/Alcian blue positive (insert) or positive for all three are visible as a yellowish green with dark brown border. E, F, G and H. Sections stained only with F2 antibody. E, F and G. Varying abundance of mucous acini stained positive for sulfo-Lewis^a antigen. H. A damaged duct immersed in a focus of inflammatory cells. Images are representative of data from 16 controls and 18 patients. Bars: correspond to 50 μ m (A, C, E, F and G), 20 μ m (B and H) or 100 μ m (D).

(fig 1). Importantly, levels of sulfation were substantially reduced in gland extracts obtained from patients (fig 3). Additionally, decreased staining for SO₃Gal β 1-3GlcNAc moieties and total sulfate oligosaccharides present in mucous acini was observed (figs 5 and 6).

Post-translational processing of mucins, including *O/N*-glycosylation and sulfation, occur in the Golgi complex.²² Since our current understanding of the regulation of glycosyltransferases/sulfotransferases is limited,²³ pin-pointing the defect in sulfation pathways that could explain the observed lower levels of sulfated moieties in mucous acinar cells of patients is difficult. Lower expression levels and/or lower enzymatic activity of sulfotransferases, reduced amounts of substrates (eg, oligosaccharide moieties, sulfate groups, etc.)

and/or an increased activity of sulfatases could explain the results of this study. Although sulfatases are thought to be located in lysosomes, more recent evidence favours the existence of a novel non-lysosomal sulfatase pool in the Golgi complex, as well as at the cell surface.²⁴ Thus, the Golgi complex could be the organelle responsible for the changes reported in this study; however, further work is necessary to provide a conclusive explanation for decreased sulfation observed in patients with Sjögren syndrome.

In human myeloid cells, tumour necrosis factor (TNF) α stimulates sulfation of GlcNAc present in the cell adhesion glycoprotein CD44, possibly by activating a GlcNAc6sulfotransferase that modulates the degree of sulfation of *N*- and *O*-linked glycans.²⁵ By contrast, treatment of cultured

Figure 5 Relationship between sulfo-Lewis^a positive mucous acini and salivary flow. A. Values for control individuals and patients with high (↑) and low (↓) unstimulated salivary flow (USF) are shown. B. Percentage of sulfo-Lewis^a mucous acini in controls and patients. C. Spearman correlation between sulfo-Lewis^a positive mucous acini and salivary flow in control individuals and patients. D. USF: unstimulated salivary flow, SS: patients with Sjögren syndrome.

bovine articular synoviocytes with TNF α caused a decrease in Gal3sulfotransferase activity,²⁶ suggesting a cell type- and sulfotransferase-specific regulation of sulfation. Additionally, these data indicate that the stimulation of an inflammatory response could alter the ratio of specific sulfated glycan structures present in a cell. Since TNF α levels are elevated in patients with Sjögren syndrome, inhibition of some sulfotransferase may provide an explanation for the low levels of glycoprotein sulfation detected in these patients. However, no correlation was observed between reduced sulfation and focus score (data not shown).

A striking correlation was detected between reduced levels of total sulfated oligosaccharides and the degree of basal lamina

disorganisation observed (fig 6). Receptors (integrins) located in the basolateral plasma membrane interact with basal lamina proteins and thereby trigger a variety of cellular responses, including secretory processes.^{27 28} Thus, if these membrane receptors are surrounded by a modified environment, changes in the interaction between proteins of both compartments could alter receptor functionality, even under circumstances where ligands or agonists are still present.^{27 28} Previous studies have reported variations in the organisation and expression of several laminins and nidogens in acini of patients with Sjögren syndrome. Such changes may affect acinar cell differentiation and polarisation.^{19 29} Altered signalling events potentially contribute to differential engagement of, for instance, the secretory

Figure 6 Microdensitometric analysis of total sulfate in mucous acini of labial salivary glands from control individuals and patients with Sjögren syndrome. A. Box plot indicating that absorbance expressed in AU for Alcian blue positive areas was higher in control individuals than in patients. B and C. Double staining with Alcian blue pH 1.0 and laminin in microphotographs of salivary gland samples from controls (B) and patients (C). Bars in B and C: 50 μ m. AU: arbitrary units.

Extended report

machinery. Thus, alterations in the input to signal relationship due to basal lamina disorganisation may represent a causative factor leading to acinar mucous cell dedifferentiation and alterations in post-translational processing of glycoproteins like MUC5B. The factors contributing to such changes in basal lamina surrounding acini in patients with Sjögren syndrome are currently under investigation.

No correlation between unstimulated salivary flow and the percentage of mucous acini with sulfo-Lewis^x antigen was found (fig 5C,D). The mucins, in particular MUC5B, play an important role in lubrication, since they maintain hydration via interactions between water molecules and hydrophilic moieties, such as sulfate groups, sialyl acid and hydroxyl groups. Our data indicate that the extent of MUC5B sialylation was low and no statistically significant differences were observed between patients and control individuals (data not shown). Thus, independent of the unstimulated salivary flow measured, the dry mouth sensation observed in all patients is currently best explained by reduced sulfation of MUC5B and other mucins present in these glands.

It is important to note that all patients analysed in this study fulfil the criteria to be diagnosed with this disease, with the exception of the unstimulated salivary flow values detected in 7/18 patients (fig 5). This strengthens the aforementioned conclusion that the oral sensation does not depend exclusively on the amount of water or quantity of saliva, but rather on the quality of saliva and the presence of specific components, such as sulfation.

In mucins, sulfated and sialic acid residues interact with Ca²⁺ and H⁺ generating interstrand crosslinks that displace water molecules and compact the mucin granule. Thus, low sulfation of mucins will impact unfavourably on secretory granule assembly.^{30–31} During exocytosis, these ions are replaced by Na⁺ and water; however, under conditions of low sulfation of mucins, such exchange does not occur and as a consequence insufficiently hydrated mucins are secreted.

Interestingly, Saari *et al* reported high concentrations of mucous glycoprotein 1 in resting whole saliva of patients with Sjögren syndrome, supporting the hypothesis that low water retention capacity could explain xerostomia.¹⁵

In conclusion, loss of mucin and particularly MUC5B sulfation was observed in the mucous acini from labial salivary glands of patients with Sjögren syndrome. This molecular change did not appear to relate to alterations in saliva volume. Instead, reduced water content of mucins with low sulfation may provide an explanation for the dry mouth sensation. Thus, we propose that post-translational modifications of MUC5B, rather than changes in mucin levels per se, play a role in salivary gland malfunction observed in patients with Sjögren syndrome and could contribute significantly to xerostomia. An important corollary of this study is that future treatments for patients with Sjögren syndrome should include not only enhanced production/intake of water but also, more importantly, an increased capacity to retain it, for example, by modulating the synthesis of mucins with appropriate post-translational processing.

Acknowledgements: The authors thank Dr Jorge Sans Puroja (Unidad de análisis integral Cesat, ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile) for help with in microdensitometric studies.

Funding: This work was supported by grants (to M-JG, SA, CM) from FONDECYT-CHILE 1020755, 1050192. PP and MB were supported by PhD fellowships granted by Conicyt, Mecesup-Postgraduate University of Chile 99-03 and Laboratorio Tecnico-Farma-Chile. LL was supported by FONDECYT-CHILE 1040390, AFGQ by FONDAP 15010006.

Competing interests: None.

Ethics approval: This study was conducted according to the guidelines of the Ethics Committee of the Faculty of Medicine, University of Chile.

REFERENCES

1. Anaya JM, Tatal N. Sjögren's syndrome comes of age. *Semin Arthritis Rheum* 1999;**28**:355–9.
2. Dawson LJ, Stanbury J, Venn N, Hasdimir B, Rogers SN, Smith PM. Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. *Arthritis Rheum* 2006;**54**:1165–73.
3. Fox RI, Kang HI, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. *J Immunol* 1994;**152**:5532–9.
4. Kontinen YT, Sorsa T, Hukkanen M, Segerberg M, Kuhlefelt-Sundstrom M, Malmstrom M, *et al*. Topology of innervation of labial salivary glands by protein gene product 9.5 and synaptophysin immunoreactive nerves in patients with Sjögren's syndrome. *J Rheumatol* 1992;**19**:30–7.
5. Fox RI, Tornwall J, Michelson P. Current issues in the diagnosis and treatment of Sjögren's syndrome. *Curr Opin Rheumatol* 1999;**11**:364–71.
6. Delporte C, Steinfeld S. Distribution and roles of aquaporins in salivary glands. *Biochim Biophys Acta* 2006;**1758**:1061–70.
7. Dawson LJ, Fox PC, Smith PM. Sjögren's syndrome – the non-apoptotic model of glandular hypofunction. *Rheumatology (Oxford)* 2006;**45**:792–8.
8. Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjögren's syndrome: where are we, and where are we going? *Arthritis Rheum* 2005;**52**:2984–95.
9. Molina C, Aliende C, Aguilera S, Kwon YJ, Leyton L, Martinez B, *et al*. Basal lamina disorganisation of the acini and ducts of labial salivary glands from patients with Sjögren's syndrome: association with mononuclear cell infiltration. *Ann Rheum Dis* 2006;**65**:178–83.
10. Goicovich E, Molina C, Perez P, Aguilera S, Fernandez J, Olea N, *et al*. Enhanced degradation of proteins of the basal lamina and stroma by matrix metalloproteinases from the salivary glands of Sjögren's syndrome patients: correlation with reduced structural integrity of acini and ducts. *Arthritis Rheum* 2003;**48**:2573–84.
11. da Costa SR, Wu K, Veigh MM, Pidgeon M, Ding C, Schechter JE, *et al*. Male NOD mouse external lacrimal glands exhibit profound changes in the exocytotic pathway early in postnatal development. *Exp Eye Res* 2006;**82**:33–45.
12. Thornton DJ, Khan N, Mehrotra R, Howard M, Veerman ECI, Packer NH, *et al*. Salivary mucin MG1 is comprised almost entirely of different glycosylated forms of the MUC5B gene product. *Glycobiology* 1999;**9**:293–302.
13. Thomson KA, Prakobphol A, Leffler H, Reddy MS, Levine MJ, Fisher SJ, *et al*. The salivary mucin MG1 (MUC5B) carries a repertoire of unique oligosaccharides that is large and diverse. *Glycobiology* 2002;**12**:1–14.
14. Nieuw Amerongen AV, Bolscher JGM, Veerman ECI. Salivary mucins: protective functions in relation to their diversity. *Glycobiology* 1995;**5**:733–40.
15. Saari H, Halinen S, Ganlov K, Sorsa T, Kontinen YT. Salivary mucous glycoprotein MG1 in Sjögren's syndrome. *Clin Chim Acta* 1997;**259**:83–96.
16. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, *et al*. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002;**61**:554–8.
17. Daniels TE. Labial salivary gland biopsy in Sjögren's syndrome. Assessment as a diagnostic criterion in 362 suspected cases. *Arthritis Rheum* 1984;**27**:147–56.
18. Perez P, Kwon YJ, Aliende C, Leyton L, Aguilera S, Molina C, *et al*. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios. *Arthritis Rheum* 2005;**52**:2751–60.
19. Kwon YJ, Perez P, Aguilera S, Molina C, Leyton L, Aliende C, *et al*. Involvement of specific laminins and nidogens in the active remodeling of the basal lamina of labial salivary glands from patients with Sjögren's syndrome. *Arthritis Rheum* 2006;**54**:3465–75.
20. Choudhury A, Singh RK, Moniaux N, El-Metwally TH, Aubert JP, Batra SK. Retinoic acid-dependent transforming growth factor-β 2-mediated induction of MUC4 mucin expression in human pancreatic tumor cells follows retinoic acid receptor-α signaling pathway. *J Biol Chem* 2000;**275**:33929–36.
21. Nielsen PA, Mandel U, Therkildsen MH, Clausen H. Differential expression of human high-molecular-weight salivary mucin (MG1) and low-molecular-weight salivary mucin (MG2). *J Dent Res* 1996;**75**:1820–6.
22. Rath VL, Verdugo D, Hemmerich S. Sulfotransferase structural biology and inhibitor discovery. *Drug Discov Today* 2004;**9**:1003–11.
23. Hempel N, Wang H, LeCluyse EL, McManus ME, Negishi M. The human sulfotransferase SULT1A1 gene is regulated in a synergistic manner by Sp1 and GA binding protein. *Mol Pharmacol* 2004;**66**:1690–701.
24. Ohto T, Uchida H, Yamazaki H, Keino-Masu K, Matsui A, Masu M. Identification of a novel nonlysosomal sulphatase expressed in the floor plate, choroid plexus and cartilage. *Genes Cells* 2002;**7**:173–85.
25. Delcomenne M, Kannagi R, Johnson N. TNF-α increases the carbohydrate sulfation of CD44: induction of 6-sulfo N-acetyl lactosamine on N- and O-linked glycans. *Glycobiology* 2002;**12**:613–22.

26. **Yang X**, Lehotay M, Anastassiades T, Harrison M, Brockhausen I. The effect of TNF- α on glycosylation pathways in bovine synoviocytes. *Biochem Cell Biol* 2004;**82**:559–68.
27. **Parnaud G**, Hammar E, Rouiller DG, Armanet M, Halban PA, Bosco D. Blockade of β 1 integrin-laminin-5 interaction affects spreading and insulin secretion of rat β -cells attached on extracellular matrix. *Diabetes* 2006;**55**:1413–20.
28. **Andersson SV**, Hamm-Alvarez SF, Gierow JP. Integrin adhesion in regulation of lacrimal gland acinar cell secretion. *Exp Eye Res* 2006;**83**:543–53.
29. **Laine M**, Virtanen I, Salo T, Kontinen YT. Segment-specific but pathologic laminin isoform profiles in human labial salivary glands of patients with Sjögren's syndrome. *Arthritis Rheum* 2004;**50**:3968–73.
30. **Espinosa M**, Noe G, Troncoso C, Ho SB, Villalon M. Acidic pH and increasing [Ca(2+)] reduce the swelling of mucins in primary cultures of human cervical cells. *Hum Reprod* 2002;**17**:1964–72.
31. **Perez-Vilar J**. Mucin granule intraluminal organization. *Am J Respir Cell Mol Biol* 2007;**36**:183–90.

Keep up to date: sign up for our alerting services

Find out automatically when an article is published on a specific topic or by a particular author. We can also alert you when an article is cited or if an eLetter or correction is published. You can also choose to be alerted when a new issue is published online [and when we post articles Online First]. Check out the New Content Alerts and Citation tracker from the Online tools section on the home page.